Medicine and Dentistry
Congestive Heart Failure
100%
Empagliflozin
77%
Ejection Fraction
68%
Placebo
48%
Heart Failure with Preserved Ejection Fraction
33%
Randomized Clinical Trial
27%
Hemodynamic
27%
Sodium Glucose Cotransporter 2 Inhibitor
22%
Heart Failure with Reduced Ejection Fraction
19%
Pulmonary Artery Occlusion Pressure
17%
Dapagliflozin
15%
Heart Left Ventricle Ejection Fraction
12%
Randomized Controlled Trial
10%
Maturity Onset Diabetes of the Young
10%
Accelerometer
9%
Exercise Test
9%
Myopathy
7%
Biological Marker
7%
Heart Output
7%
Diastolic Dysfunction
6%
Exercise Intolerance
6%
Angiotensin Receptor
6%
Contracture
6%
Mitral Insufficiency
6%
Growth Differentiation Factor 15
6%
Glomerular Filtration Rate
6%
Neprilysin
6%
Hypoxemia
6%
Erythropoiesis
6%
Aortic Stenosis
6%
Pulmonary Artery
6%
Exercise
6%
New York Heart Association Class
6%
Enkephalinase Inhibitor
5%
Pressure Flow Relationship
5%
Brain Natriuretic Peptide
5%
Amino Terminal Sequence
5%
End-Diastolic Volume
5%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
72%
Empagliflozin
69%
Placebo
42%
Heart Failure with Preserved Ejection Fraction
20%
Sodium Glucose Cotransporter 2 Inhibitor
19%
Heart Failure with Reduced Ejection Fraction
14%
Randomized Clinical Trial
14%
Non Insulin Dependent Diabetes Mellitus
11%
Randomized Controlled Trial
10%
Dapagliflozin
8%
Biological Marker
7%
Angiotensin Receptor
6%
Growth Differentiation Factor 15
6%
Membrane Metalloendopeptidase
6%
Myopathy
6%
Enkephalinase Inhibitor
5%
Brain Natriuretic Peptide
5%
